Lv1
68 积分 2026-02-25 加入
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
9天前
已完结
Dual MYC and GSPT1 Protein Degrader for MYC-Driven Hematologic Malignancies
9天前
已完结
Anti-BCMA/GPRC5D CAR T in relapsed or refractory multiple myeloma patients with extraosseous extramedullary disease
9天前
已完结
Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity
10天前
已完结
Sequential CD19-20 CAR T-cell therapy for refractory/relapsed diffuse large B-cell lymphoma
16天前
已完结
How I Treat Plasma Cell Leukemia
1个月前
已完结
Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma
1个月前
已完结
Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma
1个月前
已关闭
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
1个月前
已完结
CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia
3个月前
已完结
皖公网安备34019202002308
